Urinary cell-free microRNA biomarker could discriminate bladder cancer from benign hematuria

Int J Cancer. 2019 Jan 15;144(2):380-388. doi: 10.1002/ijc.31849. Epub 2018 Nov 13.

Abstract

The most common symptom of bladder cancer (BC) is hematuria. However, not all patients with hematuria are diagnosed with BC. Here, we explored a novel method to discriminate BC from hematuria under nonmalignant conditions by measuring differences in urinary cell-free microRNA (miRNA) expression between patients with BC and those with hematuria. A multicenter study was performed using 543 urine samples obtained from the National Biobank of Korea, including 326 BC, 174 hematuria and 43 pyuria without cancer. The urinary miR-6124 to miR-4511 ratio was considerably higher in BC than in hematuria or pyuria, and enabled the discrimination of BC from patients with hematuria at a sensitivity of >90% (p < 0.001). Conclusively, the proposed noninvasive diagnostic tool based on the expression ratio of urinary cell-free miR-6124 to miR-4511 can reduce unnecessary cystoscopies in patients with hematuria undergoing evaluation for BC, with a minimal loss in sensitivity for detecting cancer.

Keywords: bladder cancer; hematuria; miRNA; noninvasive biomarker.

Publication types

  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Biomarkers, Tumor / urine*
  • Circulating MicroRNA / urine*
  • Female
  • Hematuria / diagnosis*
  • Humans
  • Male
  • Middle Aged
  • Sensitivity and Specificity
  • Urinary Bladder Neoplasms / diagnosis
  • Urinary Bladder Neoplasms / urine*

Substances

  • Biomarkers, Tumor
  • Circulating MicroRNA